---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-001109"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T11:23:23.073513+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma prices $20M public offering of units and warrants to fund operations through 2025

## Summary
- Gross proceeds ~$20M from 40M units at $0.50/unit; each unit includes one share or Pre-Funded Warrant plus two Series A and B Warrants at $0.625 exercise.
- Series A Warrants exercisable after stockholder approval, expire 60 months; Series B Warrants exercisable after approval, expire 30 months with cashless option.
- Aegis Capital Corp. sole book-runner; underwriter has 45-day option to purchase up to 15% additional shares/warrants for over-allotments.
- Expected close Jan 7, 2025; net proceeds for general corporate purposes and development of ABP-450 botulinum toxin biosimilar.
- CEO Marc Forth: capital sufficient through 2025; plans BPD Type 2 meeting with FDA in 2025 to discuss next steps.

## SEC filing metadata
- accession: 0001104659-25-001109
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000110465925001109/0001104659-25-001109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000110465925001109/tm2432042d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-001109
- JSON: https://secwatch.observer/filing/0001104659-25-001109.json
- Plain text: https://secwatch.observer/filing/0001104659-25-001109.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.